Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human trophoblast stem cell-derived natural killer cells
- Development stage
- Unknown
- Lead developer
- Accelerated Biosciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Human trophoblast stem cell-derived natural killer cells are an investigational **allogeneic NK cell therapy** manufactured by differentiating human trophoblast stem cells into cytotoxic natural killer cells for adoptive immunotherapy. The proposed mechanism is innate immune-mediated killing of malignant or otherwise abnormal cells through endogenous NK-cell recognition systems rather than a single defined drug-receptor interaction, with expected activity involving activating NK receptors, perforin and granzyme release, and antibody-independent cytotoxicity. Based on the name provided, this appears to describe a platform or product concept rather than a clearly identified branded clinical-stage drug with a uniquely attributable developer, manufacturer, or validated trial program; consequently, available drug-specific development and target-level details are not well established from the term alone.
- Other names
- human trophoblast stem cell-derived natural killer cellstrophoblast stem cell-derived natural killer cellshTSC-derived natural killer cellshTSC-derived NK cells
Beyond the preview
Go deeper on human trophoblast stem cell-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human trophoblast stem cell-derived natural killer cells.